NCT00937131View on ClinicalTrials.gov

The Use of Rituximab in Acute Thrombotic Thrombocytopenic Purpura (TTP)

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions
Thrombotic Thrombocytopenic Purpura (TTP)
Interventions
DRUG

Rituximab

Concentrate for solution for infusion, Intravenous use, 375mg/m2, Maximum 8 weekly infusions

Trial Locations (3)

EC1A 7BE

St Bartholomew's Hospital, London

SE1 7EH

St Thomas Hosptial, London

W1

University College London Hospitals, London

All Listed Sponsors
lead

University College, London

OTHER

NCT00937131 - The Use of Rituximab in Acute Thrombotic Thrombocytopenic Purpura (TTP) | Biotech Hunter | Biotech Hunter